Maze Therapeutics (MAZE) Competitors

$26.43 -0.53 (-1.97%)

Closing price 04:00 PM Eastern

Extended Trading

$26.44 +0.01 (+0.04%)

As of 04:45 PM Eastern

MAZE vs. APGE, INDV, DNTH, KNSA, and NAMS

Should you buy Maze Therapeutics stock or one of its competitors? MarketBeat compares Maze Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maze Therapeutics include Apogee Therapeutics (APGE), Indivior (INDV), Dianthus Therapeutics (DNTH), Kiniksa Pharmaceuticals International (KNSA), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does Maze Therapeutics compare to Apogee Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Apogee Therapeutics had 4 more articles in the media than Maze Therapeutics. MarketBeat recorded 9 mentions for Apogee Therapeutics and 5 mentions for Maze Therapeutics. Apogee Therapeutics' average media sentiment score of 0.91 beat Maze Therapeutics' score of 0.13 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Apogee Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Apogee Therapeutics' return on equity of -32.64% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.89%	-32.74%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 149.72%. Apogee Therapeutics has a consensus price target of $112.73, indicating a potential upside of 34.35%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Maze Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Apogee Therapeutics	1 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.78

Maze Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.85	-$131.12M	-$3.23	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Maze Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Maze Therapeutics and Apogee Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Maze Therapeutics compare to Indivior?

Maze Therapeutics (NASDAQ:MAZE) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Indivior had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 7 mentions for Indivior and 5 mentions for Maze Therapeutics. Indivior's average media sentiment score of 1.56 beat Maze Therapeutics' score of 0.13 indicating that Indivior is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indivior	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

60.3% of Indivior shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 0.7% of Indivior shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to Maze Therapeutics' net margin of 0.00%. Maze Therapeutics' return on equity of -36.89% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.89%	-32.74%
Indivior	19.44%	-219.26%	29.40%

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 149.72%. Indivior has a consensus price target of $39.33, indicating a potential upside of 3.97%. Given Maze Therapeutics' higher probable upside, research analysts plainly believe Maze Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Indivior has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.85	-$131.12M	-$3.23	N/A
Indivior	$1.24B	3.72	$210M	$1.95	19.40

Maze Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Indivior has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Indivior beats Maze Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to Dianthus Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Dianthus Therapeutics had 12 more articles in the media than Maze Therapeutics. MarketBeat recorded 17 mentions for Dianthus Therapeutics and 5 mentions for Maze Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.12 beat Maze Therapeutics' score of 0.13 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.5% of Dianthus Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by company insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Maze Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.89%	-32.74%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Maze Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 149.72%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 38.06%. Given Maze Therapeutics' higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.85	-$131.12M	-$3.23	N/A
Dianthus Therapeutics	$1.34M	3,491.91	-$162.34M	-$4.13	N/A

Summary

Maze Therapeutics beats Dianthus Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	6.65	$59.01M	$0.90	65.04
Maze Therapeutics	$167.50M	7.85	-$131.12M	-$3.23	N/A

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Maze Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Maze Therapeutics	N/A	-36.89%	-32.74%

Kiniksa Pharmaceuticals International currently has a consensus price target of $60.86, indicating a potential upside of 3.96%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 149.72%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 53.5% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

In the previous week, Maze Therapeutics had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 5 mentions for Maze Therapeutics and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Maze Therapeutics' score of 0.13 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kiniksa Pharmaceuticals International beats Maze Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Maze Therapeutics compare to NewAmsterdam Pharma?

Maze Therapeutics (NASDAQ:MAZE) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Maze Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.89%	-32.74%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Maze Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 149.72%. NewAmsterdam Pharma has a consensus target price of $48.00, indicating a potential upside of 30.15%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Maze Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	7.85	-$131.12M	-$3.23	N/A
NewAmsterdam Pharma	$22.50M	188.45	-$203.82M	-$1.79	N/A

In the previous week, NewAmsterdam Pharma had 15 more articles in the media than Maze Therapeutics. MarketBeat recorded 20 mentions for NewAmsterdam Pharma and 5 mentions for Maze Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.58 beat Maze Therapeutics' score of 0.13 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Maze Therapeutics has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats Maze Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.32B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-10.45	18.81	20.87	25.61
Price / Sales	7.85	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	3.58	6.75	9.86	6.71
Net Income	-$131.12M	$24.11M	$3.55B	$333.77M
7 Day Performance	3.77%	0.11%	-0.26%	0.40%
1 Month Performance	-4.52%	0.87%	1.39%	4.03%
1 Year Performance	191.72%	78.18%	41.07%	36.33%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	2.3589 of 5 stars	$26.43 -2.0%	$66.00 +149.7%	+173.4%	$1.32B	$167.50M	N/A	121	Earnings Report
APGE Apogee Therapeutics	2.9732 of 5 stars	$83.03 +1.5%	$112.73 +35.8%	+111.2%	$5.14B	N/A	N/A	91	Earnings Report
INDV Indivior	3.7624 of 5 stars	$39.50 -0.3%	$39.33 -0.4%	+242.7%	$4.82B	$1.29B	20.26	1,051	Positive News
DNTH Dianthus Therapeutics	3.083 of 5 stars	$86.84 +1.6%	$117.82 +35.7%	+355.1%	$4.74B	$2.04M	N/A	80	Positive News
KNSA Kiniksa Pharmaceuticals International	3.425 of 5 stars	$58.60 +2.9%	$60.86 +3.9%	+130.9%	$4.48B	$677.56M	65.11	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. APGE, INDV, DNTH, KNSA, and NAMS

How does Maze Therapeutics compare to Apogee Therapeutics?

Summary

How does Maze Therapeutics compare to Indivior?

Summary

How does Maze Therapeutics compare to Dianthus Therapeutics?

Summary

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

How does Maze Therapeutics compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. APGE, INDV, DNTH, KNSA, and NAMS

How does Maze Therapeutics compare to Apogee Therapeutics?

Does the media prefer MAZE or APGE?

Do institutionals and insiders have more ownership in MAZE or APGE?

Is MAZE or APGE more profitable?

Do analysts prefer MAZE or APGE?

Which has stronger earnings & valuation, MAZE or APGE?

Which has more volatility & risk, MAZE or APGE?

Summary

How does Maze Therapeutics compare to Indivior?

Does the media prefer MAZE or INDV?

Do institutionals and insiders have more ownership in MAZE or INDV?

Is MAZE or INDV more profitable?

Do analysts prefer MAZE or INDV?

Which has stronger earnings & valuation, MAZE or INDV?

Which has more volatility & risk, MAZE or INDV?

Summary

How does Maze Therapeutics compare to Dianthus Therapeutics?

Does the media favor MAZE or DNTH?

Do insiders & institutionals have more ownership in MAZE or DNTH?

Is MAZE or DNTH more profitable?

Which has more risk & volatility, MAZE or DNTH?

Do analysts prefer MAZE or DNTH?

Which has higher earnings and valuation, MAZE or DNTH?

Summary

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Which has better earnings and valuation, KNSA or MAZE?

Is KNSA or MAZE more profitable?

Do analysts recommend KNSA or MAZE?

Do institutionals & insiders have more ownership in KNSA or MAZE?

Which has more risk & volatility, KNSA or MAZE?

Does the media refer more to KNSA or MAZE?

Summary

How does Maze Therapeutics compare to NewAmsterdam Pharma?

Is MAZE or NAMS more profitable?

Do analysts recommend MAZE or NAMS?

Do institutionals and insiders have more ownership in MAZE or NAMS?

Which has better valuation and earnings, MAZE or NAMS?

Does the media prefer MAZE or NAMS?

Which has more risk and volatility, MAZE or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools